Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... Westminster, CO (PRWEB) August 27, 2014 ... image analysis services to the pharmaceutical and medical ... and expansion. The fast growing company has consolidated ... in Aurora and Boulder to Westminster, CO, just north ... and Histology Lab, 7575 W. 103rd Ave., Suite 100, ...
(Date:8/27/2014)... 2014 Tris Pharma, a specialty pharmaceutical company ... that it has been selected as an award winner ... 2014 Awards for Excellence competition in the Business ... of judges from SCORE (Counselors to America,s Small Business) ... honored at a gala event to be held on ...
Breaking Biology Technology:Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Flagship Biosciences Announces Relocation and Expansion 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... Pa., Aug. 24 MEDRAD, Inc. has signed a ... to study the impact of automated Fluoro-deoxy-glucose (FDG) administration ... procedures. Clinicians at Moffitt Cancer Center in Tampa, ... measure and infuse patient-specific FDG doses while industrial engineers ...
... , , SAN DIEGO, Aug. ... today announced that Mark Booth has joined the Company as ... of commercial and business development experience to Orexigen. Most ... (TPNA) where he presided over the commercial, medical and scientific ...
... , KVISTGAARD, Denmark, August ... that the US authorities have initiated,negotiations for a ... the,IMVAMUNE(R) smallpox vaccine. This potential new project will ... Advanced Research and,Development Authority) contract for the procurement ...
Cached Biology Technology:MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 2MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 3MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 4Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer 2Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R) 2
(Date:8/27/2014)... getting effective doses of the HIV drug maraviroc, a ... studies, completed before the drug was licensed in 2007, ... is key to removing maraviroc from the body. The ... the protein including nearly half of African-Americans ... to those who lack the protein even when given ...
(Date:8/27/2014)... grass species frequently found in forests has created a ... American toads, a new University of Georgia study has ... the U.S. in the early 1900s, is one of ... more than a dozen states in the past century, ... in forests, it can survive in widely diverse ecosystems ...
(Date:8/27/2014)... what is described by the Volunteer Wildfire Services of ... Cape provincial government warned residents in certain parts of ... veld fires. A high veld fire danger rating ... coast in the Great Kei and Mnquma area. ... thunderstorms. The thunderstorms bring lightning strikes and subsequent ...
Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
... great mysteries of life is how it began. What physical process ... a living cell? For more than a century, scientists have ... life. Until recently, their focus has been trained on how the ... early Earth, or perhaps in space. But because it happened so ...
... firing in a brain reward circuit instantly rendered mice ... a study supported by the National Institutes of Health ... mimic the pattern, previously resilient mice instantly succumbed to ... they avoided other animals and lost their sweet ...
... of Notre Dame biochemist Anthony S. Serianni is providing ... and treating diabetes. Serianni points out that biological ... human body from the natural breakdown of the simple ... in diabetic patients because glucose concentrations in the blood ...
Cached Biology News:ASU researchers propose new way to look at the dawn of life 2ASU researchers propose new way to look at the dawn of life 3Stress-resilience/susceptibility traced to neurons in reward circuit 2Stress-resilience/susceptibility traced to neurons in reward circuit 3Stress-resilience/susceptibility traced to neurons in reward circuit 4Notre Dame research may have important implications for combating diabetes 2
... centrifugal filters are disposable microfiltration devices for the ... the range 100 l to 500 l. They ... 2.2 ml centrifuge tubes. Product Features: ... Low hold up volume ( Fast ...
... The ClearSpin Filter is a novel disposable ... the clarification of bacterial lysates in plasmid ... is a novel, disposable spin filtration device ... bacterial lysates in plasmid purification procedures. The ...
... fixed-angle microcentrifuge rotor at RCF up ... filters consist of a membrane-containing filter ... filter by centrifugation for bacteria removal, ... of cells from media and DNA ...
... C, 0.7 mm depth • Reusable, press-to-seal ... be quickly assembled and disassembled for hybridizing ... of any thickness with up to a ... chambers per slide. Minimize specimen handling, eliminate ...
Biology Products: